Home The Word Brain Fast Track My Amedeo FAQ About Flying Publisher   

Fast Track

OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

Free Abstracts

  Multiple Sclerosis

  Free Subscription


Articles published in J Neurol Sci

Retrieve available abstracts of 181 articles:
HTML format
Text format



Single Articles


    March 2018
  1. FENU G, Lorefice L, Arru M, Sechi V, et al
    Cognition in multiple sclerosis: Between cognitive reserve and brain volume.
    J Neurol Sci. 2018;386:19-22.
    PubMed     Text format     Abstract available


    February 2018
  2. MORROW SA, Rosehart H, Sener A, Welk B, et al
    Anti-cholinergic medications for bladder dysfunction worsen cognition in persons with multiple sclerosis.
    J Neurol Sci. 2018;385:39-44.
    PubMed     Text format     Abstract available


  3. BUNAI T, Terada T, Kono S, Yokokura M, et al
    Neuroinflammation following disease modifying therapy in multiple sclerosis: A pilot positron emission tomography study.
    J Neurol Sci. 2018;385:30-33.
    PubMed     Text format     Abstract available


  4. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2018;385:217-224.
    PubMed     Text format     Abstract available


  5. PODBIELSKA M, O'Keeffe J, Hogan EL
    Autoimmunity in multiple sclerosis: role of sphingolipids, invariant NKT cells and other immune elements in control of inflammation and neurodegeneration.
    J Neurol Sci. 2018;385:198-214.
    PubMed     Text format     Abstract available


  6. CRISTIANO E, Alonso R, Alvez Pinheiro A, Bacile EA, et al
    Corrigendum to "Argentinean recommendations on the identification of treatment failure in relapsing remitting multiple sclerosis patients" [J. Neurol. Sci. 385C (2018) 217-224].
    J Neurol Sci. 2018 Feb 12. pii: S0022-510X(18)30061.
    PubMed     Text format    


    December 2017
  7. DALLA-COSTA G, Radaelli M, Maida S, Sangalli F, et al
    Smart watch, smarter EDSS: Improving disability assessment in multiple sclerosis clinical practice.
    J Neurol Sci. 2017;383:166-168.
    PubMed     Text format     Abstract available


  8. LINGENBERG A, Laidet M, Armand S, Herrmann FR, et al
    Gait stability in patients treated by fingolimod: A longitudinal pilot study on 9 patients with multiple sclerosis.
    J Neurol Sci. 2017;383:105-107.
    PubMed     Text format    


    November 2017
  9. PEREZ-MARTIN MY, Gonzalez-Platas M, Jimenez-Sosa A, Plata-Bello J, et al
    Can fibrinolytic system components explain cognitive impairment in multiple sclerosis?
    J Neurol Sci. 2017;382:66-72.
    PubMed     Text format     Abstract available


  10. PLANCHE V, Moisset X, Morello R, Dumont E, et al
    Improvement of quality of life and its relationship with neuropsychiatric outcomes in patients with multiple sclerosis starting treatment with natalizumab: A 3-year follow-up multicentric study.
    J Neurol Sci. 2017;382:148-154.
    PubMed     Text format     Abstract available


  11. LANGESKOV-CHRISTENSEN D, Feys P, Baert I, Riemenschneider M, et al
    Performed and perceived walking ability in relation to the Expanded Disability Status Scale in persons with multiple sclerosis.
    J Neurol Sci. 2017;382:131-136.
    PubMed     Text format     Abstract available


    October 2017
  12. YOUSUF F, Dupuy SL, Tauhid S, Chu R, et al
    A two-year study using cerebral gray matter volume to assess the response to fingolimod therapy in multiple sclerosis.
    J Neurol Sci. 2017 Oct 16. pii: S0022-510X(17)34384.
    PubMed     Text format     Abstract available


  13. MILLER P, Soundy A
    The pharmacological and non-pharmacological interventions for the management of fatigue related multiple sclerosis.
    J Neurol Sci. 2017;381:41-54.
    PubMed     Text format     Abstract available


  14. KARAMI M, Mehrabi F, Allameh A, Pahlevan Kakhki M, et al
    Klotho gene expression decreases in peripheral blood mononuclear cells (PBMCs) of patients with relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2017;381:305-307.
    PubMed     Text format     Abstract available


  15. FERREIRA D, Castro P, Videira G, Filipe JP, et al
    Cerebral autoregulation is preserved in multiple sclerosis patients.
    J Neurol Sci. 2017;381:298-304.
    PubMed     Text format     Abstract available


  16. CALVI A, De Riz M, Lecchi E, Pietroboni A, et al
    Merkel cell carcinoma in a patient with relapsing-remitting multiple sclerosis treated with fingolimod.
    J Neurol Sci. 2017;381:296-297.
    PubMed     Text format    


  17. OLIVEIRA SR, Simao ANC, Alfieri DF, Flauzino T, et al
    Vitamin D deficiency is associated with disability and disease progression in multiple sclerosis patients independently of oxidative and nitrosative stress.
    J Neurol Sci. 2017;381:213-219.
    PubMed     Text format     Abstract available


  18. CORREALE J
    Follow-on products for treatment of multiple sclerosis in Latin America: An update.
    J Neurol Sci. 2017;381:153-159.
    PubMed     Text format     Abstract available


  19. BEIER M, Gromisch ES, Hughes AJ, Alschuler KN, et al
    Proposed cut scores for tests of the Brief International Cognitive Assessment of Multiple Sclerosis (BICAMS).
    J Neurol Sci. 2017;381:110-116.
    PubMed     Text format     Abstract available


  20. MCGEE JC, Minagar A
    Assessing the cerebral gray matter volume in response to fingolimod therapy in multiple sclerosis: A more analytic view.
    J Neurol Sci. 2017 Oct 13. pii: S0022-510X(17)34383.
    PubMed     Text format    


    September 2017
  21. YAMOUT BI, Said M, Hannoun S, Zeineddine M, et al
    Rebound syndrome after teriflunomide cessation in a patient with multiple sclerosis.
    J Neurol Sci. 2017;380:79-81.
    PubMed     Text format     Abstract available


  22. YANG TT, Wang L, Deng XY, Yu G, et al
    Pharmacological treatments for fatigue in patients with multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;380:256-261.
    PubMed     Text format     Abstract available


  23. GREEKE EE, Chua AS, Healy BC, Rintell DJ, et al
    Depression and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;380:236-241.
    PubMed     Text format     Abstract available


  24. IWANOWSKI P, Losy J, Kramer L, Wojcicka M, et al
    CXCL10 and CXCL13 chemokines in patients with relapsing remitting and primary progressive multiple sclerosis.
    J Neurol Sci. 2017;380:22-26.
    PubMed     Text format     Abstract available


  25. LAIDET M, Herrmann FR, Armand S, Assal F, et al
    Does fear of falling predict gait variability in multiple sclerosis?
    J Neurol Sci. 2017;380:212-214.
    PubMed     Text format     Abstract available


  26. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Corrigendum to "Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?" [J. Neurol. Sci. 378 (2017) 233-237].
    J Neurol Sci. 2017;380:19.
    PubMed     Text format    


  27. PICELLI A, Vallies G, Chemello E, Castellazzi P, et al
    Is spasticity always the same? An observational study comparing the features of spastic equinus foot in patients with chronic stroke and multiple sclerosis.
    J Neurol Sci. 2017;380:132-136.
    PubMed     Text format     Abstract available


    August 2017
  28. SANTORO M, Mirabella M, De Fino C, Bianco A, et al
    Sativex(R) effects on promoter methylation and on CNR1/CNR2 expression in peripheral blood mononuclear cells of progressive multiple sclerosis patients.
    J Neurol Sci. 2017;379:298-303.
    PubMed     Text format     Abstract available


  29. GAETANI L, Fanelli F, Riccucci I, Eusebi P, et al
    High risk of early conversion to multiple sclerosis in clinically isolated syndromes with dissemination in space at baseline.
    J Neurol Sci. 2017;379:236-240.
    PubMed     Text format     Abstract available


  30. KEUNE PM, Young WR, Paraskevopoulos IT, Hansen S, et al
    Measuring standing balance in multiple sclerosis: Further progress towards an automatic and reliable method in clinical practice.
    J Neurol Sci. 2017;379:157-162.
    PubMed     Text format     Abstract available


  31. MORSALJAHAN Z, Rafiei A, Valadan R, Abedini M, et al
    Association between interleukin-32 polymorphism and multiple sclerosis.
    J Neurol Sci. 2017;379:144-150.
    PubMed     Text format     Abstract available


    July 2017
  32. FARROKHI M, Masoudifar A, Peykanpour F
    Interleukin 17 and 10 in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017;378:63.
    PubMed     Text format    


  33. ROLF L, Muris AH, Bol Y, Damoiseaux J, et al
    Vitamin D3 supplementation in multiple sclerosis: Symptoms and biomarkers of depression.
    J Neurol Sci. 2017;378:30-35.
    PubMed     Text format     Abstract available


  34. SCARPAZZA C, Prosperini L, Mancinelli CR, De Rossi N, et al
    Is maraviroc useful in multiple sclerosis patients with natalizumab-related progressive multifocal leukoencephalopathy?
    J Neurol Sci. 2017;378:233-237.
    PubMed     Text format     Abstract available


  35. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Concerning the article "Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients".
    J Neurol Sci. 2017;378:152.
    PubMed     Text format    


    June 2017
  36. AGLIARDI C, Guerini FR, Zanzottera M, Rovaris M, et al
    Indoleamine-2,3-dioxygenase(IDO)2 polymorphisms are not associated with multiple sclerosis in Italians.
    J Neurol Sci. 2017;377:31-34.
    PubMed     Text format     Abstract available


  37. CALABRO RS, Russo M, Naro A, De Luca R, et al
    Robotic gait training in multiple sclerosis rehabilitation: Can virtual reality make the difference? Findings from a randomized controlled trial.
    J Neurol Sci. 2017;377:25-30.
    PubMed     Text format     Abstract available


  38. TRENTINI A, Castellazzi M, Romani A, Squerzanti M, et al
    Evaluation of total, ceruloplasmin-associated and type II ferroxidase activities in serum and cerebrospinal fluid of multiple sclerosis patients.
    J Neurol Sci. 2017;377:133-136.
    PubMed     Text format     Abstract available


  39. SMOLDERS J, Rolf L, Damoiseaux J, Hupperts R, et al
    On the ethics of not supplementing low 25-hydroxyvitamin D levels in a controlled study in relapsing remitting multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30383.
    PubMed     Text format    


  40. SHUKLA L, Solanki C, Kulkarni Y, Vadlamani N, et al
    Vitamin D supplementation; effects on depressive symptoms in multiple sclerosis.
    J Neurol Sci. 2017 Jun 9. pii: S0022-510X(17)30384.
    PubMed     Text format    


    May 2017
  41. JORGENSEN M, Dalgas U, Wens I, Hvid LG, et al
    Muscle strength and power in persons with multiple sclerosis - A systematic review and meta-analysis.
    J Neurol Sci. 2017;376:225-241.
    PubMed     Text format     Abstract available


  42. HEESEN C, Kleiter I, Meuth SG, Kramer J, et al
    Benefit-risk perception of natalizumab therapy in neurologists and a large cohort of multiple sclerosis patients.
    J Neurol Sci. 2017;376:181-190.
    PubMed     Text format     Abstract available


  43. BSTEH G, Monz E, Zamarian L, Hagspiel S, et al
    Combined evaluation of personality, risk and coping in MS patients: A step towards individualized treatment choice - The PeRiCoMS-Study I.
    J Neurol Sci. 2017;376:71-75.
    PubMed     Text format     Abstract available


  44. WEINSTOCK-GUTTMAN B, Nair KV, Glajch JL, Ganguly TC, et al
    Two decades of glatiramer acetate: From initial discovery to the current development of generics.
    J Neurol Sci. 2017;376:255-259.
    PubMed     Text format     Abstract available


    April 2017
  45. BOURNE T, Waltz M, Casper TC, Kavak K, et al
    Evaluating the association of allergies with multiple sclerosis susceptibility risk and disease activity in a pediatric population.
    J Neurol Sci. 2017;375:371-375.
    PubMed     Text format     Abstract available


  46. LYSANDROPOULOS AP, Mavroudakis N, Pandolfo M, El Hafsi K, et al
    HLA genotype as a marker of multiple sclerosis prognosis: A pilot study.
    J Neurol Sci. 2017;375:348-354.
    PubMed     Text format     Abstract available


  47. NOORI-ZADEH A, Mesbah-Namin SA, Saboor-Yaraghi AA
    Epigenetic and gene expression alterations of FOXP3 in the T cells of EAE mouse model of multiple sclerosis.
    J Neurol Sci. 2017;375:203-208.
    PubMed     Text format     Abstract available


  48. RUBEGNI A, Battisti C, Tessa A, Cerase A, et al
    SPG2 mimicking multiple sclerosis in a family identified using next generation sequencing.
    J Neurol Sci. 2017;375:198-202.
    PubMed     Text format     Abstract available


  49. HARTL C, Obermeier V, Gerdes LA, Brugel M, et al
    Seasonal variations of 25-OH vitamin D serum levels are associated with clinical disease activity in multiple sclerosis patients.
    J Neurol Sci. 2017;375:160-164.
    PubMed     Text format     Abstract available


  50. REEN GK, Silber E, Langdon DW
    Multiple sclerosis patients' understanding and preferences for risks and benefits of disease-modifying drugs: A systematic review.
    J Neurol Sci. 2017;375:107-122.
    PubMed     Text format     Abstract available


    February 2017
  51. ZHOU Y, Fang L, Peng L, Qiu W, et al
    TLR9 and its signaling pathway in multiple sclerosis.
    J Neurol Sci. 2017;373:95-99.
    PubMed     Text format     Abstract available


  52. WUNDES A, Bowen JD, Kraft GH, Maravilla KR, et al
    Brain pathology of a patient 7years after autologous hematopoietic stem cell transplantation for multiple sclerosis.
    J Neurol Sci. 2017;373:339-341.
    PubMed     Text format     Abstract available


  53. LANGESKOV-CHRISTENSEN M, Bisson EJ, Finlayson ML, Dalgas U, et al
    Potential pathophysiological pathways that can explain the positive effects of exercise on fatigue in multiple sclerosis: A scoping review.
    J Neurol Sci. 2017;373:307-320.
    PubMed     Text format     Abstract available


  54. FERREIRA KP, Oliveira SR, Kallaur AP, Kaimen-Maciel DR, et al
    Disease progression and oxidative stress are associated with higher serum ferritin levels in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:236-241.
    PubMed     Text format     Abstract available


  55. KAWADA T
    Poor sleep and fatigue in patients with multiple sclerosis.
    J Neurol Sci. 2017;373:143.
    PubMed     Text format    


  56. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Response to the letter to the Editor for the manuscript "Sleep and Fatigue in Multiple Sclerosis: A questionnaire-based, cross-sectional, cohort study" by Tomoyuki Kawada.
    J Neurol Sci. 2017;373:142.
    PubMed     Text format    


  57. ZAHOOR I, Haq E, Asimi R
    Multiple sclerosis in Kashmir: Where we stand.
    J Neurol Sci. 2017;373:129-133.
    PubMed     Text format     Abstract available


  58. TOGHI M, Taheri M, Arsang-Jang S, Ohadi M, et al
    SOCS gene family expression profile in the blood of multiple sclerosis patients.
    J Neurol Sci. 2017 Feb 9. pii: S0022-510X(17)30111.
    PubMed     Text format     Abstract available


    January 2017
  59. ALGAHTANI H, Marzouk Y, Algahtani R, Salman S, et al
    Autosomal Recessive Cerebellar Ataxia type 1 mimicking multiple sclerosis: A report of two siblings with a novel mutation in SYNE1 gene in a Saudi family.
    J Neurol Sci. 2017;372:97-100.
    PubMed     Text format     Abstract available


  60. MOTL RW, Sandroff BM, Pilutti LA, Klaren RE, et al
    Physical activity, sedentary behavior, and aerobic capacity in persons with multiple sclerosis.
    J Neurol Sci. 2017;372:342-346.
    PubMed     Text format     Abstract available


  61. BOESCHOTEN RE, Braamse AM, Beekman AT, Cuijpers P, et al
    Prevalence of depression and anxiety in Multiple Sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2017;372:331-341.
    PubMed     Text format     Abstract available


  62. CAMEROTA F, Celletti C, Di Sipio E, De Fino C, et al
    Focal muscle vibration, an effective rehabilitative approach in severe gait impairment due to multiple sclerosis.
    J Neurol Sci. 2017;372:33-39.
    PubMed     Text format     Abstract available


  63. SABATINO JJ JR, Newsome SD
    Stiff person syndrome masquerading as multiple sclerosis.
    J Neurol Sci. 2017;372:297-299.
    PubMed     Text format     Abstract available


  64. CRNOSIJA L, Krbot Skoric M, Gabelic T, Adamec I, et al
    Vestibular evoked myogenic potentials and MRI in early multiple sclerosis: Validation of the VEMP score.
    J Neurol Sci. 2017;372:28-32.
    PubMed     Text format     Abstract available


  65. KISIC-TEPAVCEVIC D, Pekmezovic T, Trajkovic G, Stojsavljevic N, et al
    Corrigendum to "Sexual dysfunction in multiple sclerosis: A 6-year follow-up study" [J. Neurol. Sci. 358 (2015) 317-323].
    J Neurol Sci. 2017;372:201.
    PubMed     Text format    


  66. CHALAH MA, Riachi N, Ahdab R, Mhalla A, et al
    Effects of left DLPFC versus right PPC tDCS on multiple sclerosis fatigue.
    J Neurol Sci. 2017;372:131-137.
    PubMed     Text format     Abstract available


  67. TAO C, Simpson S Jr, Taylor BV, van der Mei I, et al
    Association between human herpesvirus & human endogenous retrovirus and MS onset & progression.
    J Neurol Sci. 2017;372:239-249.
    PubMed     Text format     Abstract available


  68. BEH SC, Kildebeck E, Narayan R, Desena A, et al
    High-dose methotrexate with leucovorin rescue: For monumentally severe CNS inflammatory syndromes.
    J Neurol Sci. 2017;372:187-195.
    PubMed     Text format     Abstract available


  69. TANIKAWA M, Nakahara J, Hata J, Suzuki S, et al
    q-Space Myelin Map imaging for longitudinal analysis of demyelination and remyelination in multiple sclerosis patients treated with fingolimod: A preliminary study.
    J Neurol Sci. 2017 Jan 5. pii: S0022-510X(17)30010.
    PubMed     Text format     Abstract available


  70. KIRA JI
    q-space Myelin Map imaging: A new imaging technique for treatment evaluation in multiple sclerosis.
    J Neurol Sci. 2017 Jan 4. pii: S0022-510X(17)30009.
    PubMed     Text format    


    December 2016
  71. KOUDRIAVTSEVA T
    Body mass index and interferon-beta efficacy (and safety) in multiple sclerosis.
    J Neurol Sci. 2016;371:79-80.
    PubMed     Text format    


    November 2016
  72. HERNANDEZ ME, Holtzer R, Chaparro G, Jean K, et al
    Brain activation changes during locomotion in middle-aged to older adults with multiple sclerosis.
    J Neurol Sci. 2016;370:277-283.
    PubMed     Text format     Abstract available


  73. SQUINTANI G, Donato F, Turri M, Deotto L, et al
    Cortical and spinal excitability in patients with multiple sclerosis and spasticity after oromucosal cannabinoid spray.
    J Neurol Sci. 2016;370:263-268.
    PubMed     Text format     Abstract available


  74. O'GORMAN CM, Broadley SA
    Smoking increases the risk of progression in multiple sclerosis: A cohort study in Queensland, Australia.
    J Neurol Sci. 2016;370:219-223.
    PubMed     Text format     Abstract available


  75. DE GIGLIO L, Upadhyay N, De Luca F, Prosperini L, et al
    Corpus callosum microstructural changes associated with Kawashima Nintendo Brain Training in patients with multiple sclerosis.
    J Neurol Sci. 2016;370:211-213.
    PubMed     Text format    


  76. GAINDH D, Kavak KS, Teter B, Vaughn CB, et al
    Decreased risk of cancer in multiple sclerosis patients and analysis of the effect of disease modifying therapies on cancer risk.
    J Neurol Sci. 2016;370:13-17.
    PubMed     Text format     Abstract available


  77. GASPERINI C, Hupperts R, Lycke J, Short C, et al
    Prolonged-release fampridine treatment improved subject-reported impact of multiple sclerosis: Item-level analysis of the MSIS-29.
    J Neurol Sci. 2016;370:123-131.
    PubMed     Text format     Abstract available


  78. HUHN K, Lammer R, Zimmermann H, Lammer A, et al
    Retinal imaging and axonal degeneration in later onset multiple sclerosis.
    J Neurol Sci. 2016;370:1-6.
    PubMed     Text format     Abstract available


    October 2016
  79. NOCITI V, Losavio FA, Gnoni V, Losurdo A, et al
    Sleep and fatigue in multiple sclerosis: A questionnaire-based, cross-sectional, cohort study.
    J Neurol Sci. 2016 Oct 27. pii: S0022-510X(16)30684.
    PubMed     Text format     Abstract available


  80. EFTEKHARIAN MM, Noroozi R, Sayad A, Sarrafzadeh S, et al
    RAR-related orphan receptor A (RORA): A new susceptibility gene for multiple sclerosis.
    J Neurol Sci. 2016;369:259-62.
    PubMed     Text format     Abstract available


  81. BERNARDINI LR, Zecca C, Clerici VT, Gobbi C, et al
    Severe articular and musculoskeletal pain: An unexpected side effect of dimethyl-fumarate therapy for multiple sclerosis.
    J Neurol Sci. 2016;369:139-40.
    PubMed     Text format    


  82. YANG F, Estrada EF, Sanchez MC
    Vibration training improves disability status in multiple sclerosis: A pretest-posttest pilot study.
    J Neurol Sci. 2016;369:96-101.
    PubMed     Text format     Abstract available


  83. MANDEL JJ, Goethe EA, Patel AJ, Heck K, et al
    Newly diagnosed ganglioglioma in an adult patient with multiple sclerosis.
    J Neurol Sci. 2016;369:51-2.
    PubMed     Text format    


  84. TAWFIK TZ, Gad AH, Mehaney DA, El Nahrery E, et al
    Interleukins 17 and 10 in a sample of Egyptian relapsing remitting multiple sclerosis patients.
    J Neurol Sci. 2016;369:36-8.
    PubMed     Text format     Abstract available


    September 2016
  85. STELLMANN JP, Jlussi M, Neuhaus A, Lederer C, et al
    Fampridine and real-life walking in multiple sclerosis: Low predictive value of clinical test for habitual short-term changes.
    J Neurol Sci. 2016;368:318-25.
    PubMed     Text format     Abstract available


  86. BENITO-LEON J, Domingo-Santos A
    Gut microflora and multiple sclerosis.
    J Neurol Sci. 2016;368:254.
    PubMed     Text format    


  87. BRAMBILLA L, Rossi Sebastiano D, Aquino D, Torri Clerici V, et al
    Early effect of dalfampridine in patients with MS: A multi-instrumental approach to better investigate responsiveness.
    J Neurol Sci. 2016;368:402-7.
    PubMed     Text format     Abstract available


  88. MESSMER UCCELLI M, Traversa S, Ponzio M
    A survey study comparing young adults with MS and healthy controls on self-esteem, self-efficacy, mood and quality of life.
    J Neurol Sci. 2016;368:369-73.
    PubMed     Text format     Abstract available


  89. SACCA F, Pane C, Carotenuto A, Massarelli M, et al
    The use of medical-grade cannabis in patients non-responders to Nabiximols.
    J Neurol Sci. 2016;368:349-51.
    PubMed     Text format    


    August 2016
  90. MASUDA H, Mori M, Uzawa A, Muto M, et al
    Recovery from optic neuritis attack in neuromyelitis optica spectrum disorder and multiple sclerosis.
    J Neurol Sci. 2016;367:375-9.
    PubMed     Text format     Abstract available


  91. SANDI D, Zsiros V, Fuvesi J, Kincses ZT, et al
    Mortality in Hungarian patients with multiple sclerosis between 1993 and 2013.
    J Neurol Sci. 2016;367:329-32.
    PubMed     Text format     Abstract available


  92. CHRUZANDER C, Tinghog P, Ytterberg C, Widen Holmqvist L, et al
    Longitudinal changes in sickness absence and disability pension, and associations between disability pension and disease-specific and contextual factors and functioning, in people with multiple sclerosis.
    J Neurol Sci. 2016;367:319-25.
    PubMed     Text format     Abstract available


  93. MANTERO V, Borelli P, Rigamonti A, Fiumani A, et al
    Autoimmunity meets genetics: Multiple sclerosis in a patient with Kallmann syndrome.
    J Neurol Sci. 2016;367:256-7.
    PubMed     Text format    


  94. ABDOLLAHZADEH R, Fard MS, Rahmani F, Moloudi K, et al
    Predisposing role of vitamin D receptor (VDR) polymorphisms in the development of multiple sclerosis: A case-control study.
    J Neurol Sci. 2016;367:148-51.
    PubMed     Text format     Abstract available


  95. VIDEIRA G, Castro P, Vieira B, Filipe JP, et al
    Autonomic dysfunction in multiple sclerosis is better detected by heart rate variability and is not correlated with central autonomic network damage.
    J Neurol Sci. 2016;367:133-7.
    PubMed     Text format     Abstract available


  96. WENS I, Eijnde BO, Hansen D
    Muscular, cardiac, ventilatory and metabolic dysfunction in patients with multiple sclerosis: Implications for screening, clinical care and endurance and resistance exercise therapy, a scoping review.
    J Neurol Sci. 2016;367:107-21.
    PubMed     Text format     Abstract available


    July 2016
  97. NOURBAKHSH B, Azevedo C, Maghzi AH, Spain R, et al
    Subcortical grey matter volumes predict subsequent walking function in early multiple sclerosis.
    J Neurol Sci. 2016;366:229-33.
    PubMed     Text format     Abstract available


  98. GIORDANO A, Cimino V, Campanella A, Morone G, et al
    Low quality of life and psychological wellbeing contrast with moderate perceived burden in carers of people with severe multiple sclerosis.
    J Neurol Sci. 2016;366:139-45.
    PubMed     Text format    


    June 2016
  99. HUNTER SF, Agius M, Miller DM, Cutter G, et al
    Impact of a switch to fingolimod on depressive symptoms in patients with relapsing multiple sclerosis: An analysis from the EPOC (Evaluate Patient OutComes) trial.
    J Neurol Sci. 2016;365:190-8.
    PubMed     Text format     Abstract available


  100. IODICE R, Carotenuto A, Dubbioso R, Cerillo I, et al
    Multimodal evoked potentials follow up in multiple sclerosis patients under fingolimod therapy.
    J Neurol Sci. 2016;365:143-6.
    PubMed     Text format     Abstract available


  101. LANGESKOV-CHRISTENSEN M, Kjolhede T, Stenager E, Jensen HB, et al
    Can aerobic exercise alleviate flu-like symptoms following interferon beta-1a injections in patients with multiple sclerosis?
    J Neurol Sci. 2016;365:114-20.
    PubMed     Text format     Abstract available


  102. LI LM, Yang LN, Zhang LJ, Fu Y, et al
    Olfactory dysfunction in patients with multiple sclerosis.
    J Neurol Sci. 2016;365:34-9.
    PubMed     Text format     Abstract available


  103. ALADRO Y, Terrero R, Cerezo M, Ginestal R, et al
    Anti-JC virus seroprevalence in a Spanish multiple sclerosis cohort: JC virus seroprevalence in Spain.
    J Neurol Sci. 2016;365:16-21.
    PubMed     Text format     Abstract available


  104. KUUSISTO H, Vahvelainen T, Hamalainen P, Luukkaala T, et al
    Asymptomatic subjects differ less from their twin siblings with MS than from healthy controls in cognitive functioning. A Finnish Twin Cohort study.
    J Neurol Sci. 2016;365:50-3.
    PubMed     Text format     Abstract available


    May 2016
  105. PROSPERINI L, Fanelli F, Pozzilli C
    Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
    J Neurol Sci. 2016;364:145-7.
    PubMed     Text format     Abstract available


  106. MONTANARI E, Rottoli M, Maimone D, Confalonieri P, et al
    A 12-month prospective, observational study evaluating the impact of disease-modifying treatment on emotional burden in recently-diagnosed multiple sclerosis patients: The POSIDONIA study.
    J Neurol Sci. 2016;364:105-9.
    PubMed     Text format     Abstract available


  107. STICH O, Perera S, Berger B, Jarius S, et al
    Prevalence of neurofascin-155 antibodies in patients with multiple sclerosis.
    J Neurol Sci. 2016;364:29-32.
    PubMed     Text format     Abstract available


    April 2016
  108. BECKER J, Callegaro D, Lana-Peixoto MA, Talim N, et al
    Hypovitaminosis D association with disease activity in relapsing remitting multiple sclerosis in Brazil.
    J Neurol Sci. 2016;363:236-9.
    PubMed     Text format     Abstract available


  109. HUBBARD EA, Wetter NC, Sutton BP, Pilutti LA, et al
    Diffusion tensor imaging of the corticospinal tract and walking performance in multiple sclerosis.
    J Neurol Sci. 2016;363:225-31.
    PubMed     Text format     Abstract available


  110. FOX EJ, Wynn D, Coles AJ, Palmer J, et al
    Alemtuzumab improves neurological functional systems in treatment-naive relapsing-remitting multiple sclerosis patients.
    J Neurol Sci. 2016;363:188-94.
    PubMed     Text format     Abstract available


  111. KASSI E, Semaniakou A, Sertedaki A, Evangelopoulos ME, et al
    Sequencing analysis of the human glucocorticoid receptor (NR3C1) gene in multiple sclerosis patients.
    J Neurol Sci. 2016;363:165-9.
    PubMed     Text format     Abstract available


  112. BOSNJAK PASIC M, Hajnsek S, Panajatovic M, Vidrih B, et al
    Liposarcoma concurrence in a multiple sclerosis patient treated with interferon-beta 1b.
    J Neurol Sci. 2016;363:145-6.
    PubMed     Text format    


  113. ZHANG Z, Wang L, Sun X, Zhang L, et al
    Association of IL4 and IL4R polymorphisms with multiple sclerosis susceptibility in Caucasian population: A meta-analysis.
    J Neurol Sci. 2016;363:107-13.
    PubMed     Text format     Abstract available


  114. PEYRO SAINT PAUL L, Creveuil C, Heinzlef O, De Seze J, et al
    Efficacy and safety profile of memantine in patients with cognitive impairment in multiple sclerosis: A randomized, placebo-controlled study.
    J Neurol Sci. 2016;363:69-76.
    PubMed     Text format     Abstract available


  115. KRUPP LB, Pohl D, Ghezzi A, Boyko A, et al
    Subcutaneous interferon beta-1a in pediatric patients with multiple sclerosis: Regional differences in clinical features, disease management, and treatment outcomes in an international retrospective study.
    J Neurol Sci. 2016;363:33-8.
    PubMed     Text format     Abstract available


  116. ZIVKOVIC M, Kolakovic A, Stojkovic L, Dincic E, et al
    Renin-angiotensin system gene polymorphisms as risk factors for multiple sclerosis.
    J Neurol Sci. 2016;363:29-32.
    PubMed     Text format     Abstract available


  117. TREMLETT H, Fadrosh DW, Faruqi AA, Hart J, et al
    Gut microbiota composition and relapse risk in pediatric MS: A pilot study.
    J Neurol Sci. 2016;363:153-7.
    PubMed     Text format     Abstract available


    March 2016
  118. KIERKEGAARD M, Lundberg IE, Olsson T, Johansson S, et al
    High-intensity resistance training in multiple sclerosis - An exploratory study of effects on immune markers in blood and cerebrospinal fluid, and on mood, fatigue, health-related quality of life, muscle strength, walking and cognition.
    J Neurol Sci. 2016;362:251-7.
    PubMed     Text format     Abstract available


  119. THONE J, Kleiter I, Stahl A, Ellrichmann G, et al
    Relevance of endoglin, IL-1alpha, IL-1beta and anti-ovarian antibodies in females with multiple sclerosis.
    J Neurol Sci. 2016;362:240-3.
    PubMed     Text format     Abstract available


  120. WALKER LA, Osman L, Berard JA, Rees LM, et al
    Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS): Canadian contribution to the international validation project.
    J Neurol Sci. 2016;362:147-52.
    PubMed     Text format     Abstract available


  121. LIU Y, Morgan C, Hornung L, Tyry T, et al
    Relationship between symptom change, relapse activity and disability progression in multiple sclerosis.
    J Neurol Sci. 2016;362:121-6.
    PubMed     Text format     Abstract available


  122. AHMADI M, Emami Aleagha MS, Harirchian MH, Yarani R, et al
    Multiple sclerosis influences on the augmentation of serum Klotho concentration.
    J Neurol Sci. 2016;362:69-72.
    PubMed     Text format     Abstract available


  123. HUDA S, Cavey A, Izat A, Mattison P, et al
    Nurse led telephone assessment of expanded disability status scale assessment in MS patients at high levels of disability.
    J Neurol Sci. 2016;362:66-8.
    PubMed     Text format     Abstract available


    February 2016
  124. FERNANDEZ-MENENDEZ S, Fernandez-Moran M, Fernandez-Vega I, Perez-Alvarez A, et al
    Epstein-Barr virus and multiple sclerosis. From evidence to therapeutic strategies.
    J Neurol Sci. 2016;361:213-9.
    PubMed     Text format     Abstract available


  125. HANNA J, Feinstein A, Morrow SA
    The association of pathological laughing and crying and cognitive impairment in multiple sclerosis.
    J Neurol Sci. 2016;361:200-3.
    PubMed     Text format     Abstract available


  126. RIO J, Ruiz-Pena JL
    Short-term suboptimal response criteria for predicting long-term non-response to first-line disease modifying therapies in multiple sclerosis: A systematic review and meta-analysis.
    J Neurol Sci. 2016;361:158-67.
    PubMed     Text format    


  127. AGIOVLASITIS S, Sandroff BM, Motl RW
    Step-rate cut-points for physical activity intensity in patients with multiple sclerosis: The effect of disability status.
    J Neurol Sci. 2016;361:95-100.
    PubMed     Text format     Abstract available


  128. FAREZ MF, Correale J
    Sphingosine 1-phosphate signaling in astrocytes: Implications for progressive multiple sclerosis.
    J Neurol Sci. 2016;361:60-5.
    PubMed     Text format     Abstract available


  129. KALRON A
    Gait variability across the disability spectrum in people with multiple sclerosis.
    J Neurol Sci. 2016;361:1-6.
    PubMed     Text format     Abstract available


    January 2016
  130. SAVIN Z, Lejbkowicz I, Glass-Marmor L, Lavi I, et al
    Effect of Fampridine-PR (prolonged released 4-aminopyridine) on the manual functions of patients with Multiple Sclerosis.
    J Neurol Sci. 2016;360:102-9.
    PubMed     Text format     Abstract available


  131. ALROUGHANI R, Akhtar S, Ahmed SF, Khoury SJ, et al
    JC virus seroprevalence and seroconversion in multiple sclerosis cohort: A Middle-Eastern study.
    J Neurol Sci. 2016;360:61-5.
    PubMed     Text format     Abstract available


  132. ALVAREZ-CERMENO JC, Munoz-Negrete FJ, Costa-Frossard L, de la Maza SS, et al
    Intrathecal lipid-specific oligoclonal IgM synthesis associates with retinal axonal loss in multiple sclerosis.
    J Neurol Sci. 2016;360:41-4.
    PubMed     Text format     Abstract available


  133. DAMASCENO A, Moraes AS, Farias A, Damasceno BP, et al
    A spring to summer shift of pro-inflammatory cytokine production in multiple sclerosis patients.
    J Neurol Sci. 2016;360:37-40.
    PubMed     Text format     Abstract available


  134. MOORE P, Methley A, Pollard C, Mutch K, et al
    Cognitive and psychiatric comorbidities in neuromyelitis optica.
    J Neurol Sci. 2016;360:4-9.
    PubMed     Text format     Abstract available


    December 2015
  135. YOSHII F, Takagi S, Nagata E, Hasegawa Y, et al
    Cognitive impairment of Japanese multiple sclerosis patients: Follow-up study using BRB-N assessment tool.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  136. BEHBEHANI R, Al-Hassan AA, Al-Khars A, Sriraman D, et al
    Retinal nerve fiber layer thickness and neurologic disability in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2015;359.
    PubMed     Text format    


  137. ZAHOOR I, Asimi R, Haq E
    No evidence for a role of Ile587Val polymorphism of EIF2B5 gene in multiple sclerosis in Kashmir Valley of India.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  138. OTERO-ROMERO S, Ramio-Torrenta L, Pericot I, Carmona O, et al
    Onset-adjusted incidence of multiple sclerosis in the Girona province (Spain): Evidence of increasing risk in the south of Europe.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  139. LAMARGUE-HAMEL D, Deloire M, Saubusse A, Ruet A, et al
    Cognitive evaluation by tasks in a virtual reality environment in multiple sclerosis.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


  140. GILLI F, Li L, Campbell SJ, Anthony DC, et al
    The effect of B-cell depletion in the Theiler's model of multiple sclerosis.
    J Neurol Sci. 2015;359.
    PubMed     Text format     Abstract available


    October 2015
  141. CASTELLI L, Stocchi L, Patrignani M, Sellitto G, et al
    We-Measure: Toward a low-cost portable posturography for patients with multiple sclerosis using the commercial Wii balance board.
    J Neurol Sci. 2015 Oct 14. pii: S0022-510X(15)02484.
    PubMed     Text format     Abstract available


    September 2015
  142. KANTELE S, Karinkanta S, Sievanen H
    Effects of long-term whole-body vibration training on mobility in patients with multiple sclerosis: A meta-analysis of randomized controlled trials.
    J Neurol Sci. 2015 Sep 25. pii: S0022-510X(15)02445.
    PubMed     Text format     Abstract available


  143. AYACHE SS, Chalah MA, Al-Ani T, Farhat WH, et al
    Tremor in multiple sclerosis: The intriguing role of the cerebellum.
    J Neurol Sci. 2015 Sep 25. pii: S0022-510X(15)02448.
    PubMed     Text format    


  144. PAU M, Coghe G, Corona F, Marrosu MG, et al
    Effect of spasticity on kinematics of gait and muscular activation in people with Multiple Sclerosis.
    J Neurol Sci. 2015 Sep 18. pii: S0022-510X(15)02440.
    PubMed     Text format     Abstract available


  145. FARJAM M, Zhang GX, Ciric B, Rostami A, et al
    Emerging immunopharmacological targets in multiple sclerosis.
    J Neurol Sci. 2015 Sep 14. pii: S0022-510X(15)02434.
    PubMed     Text format     Abstract available


  146. DARIJA KT, Tatjana P, Goran T, Nebojsa S, et al
    Sexual dysfunction in multiple sclerosis: A 6-year follow-up study.
    J Neurol Sci. 2015 Sep 10. pii: S0022-510X(15)02111.
    PubMed     Text format     Abstract available


  147. TANIK N, Serin HI, Celikbilek A, Inan LE, et al
    Olfactory bulb and olfactory sulcus depths are associated with disease duration and attack frequency in multiple sclerosis patients.
    J Neurol Sci. 2015 Sep 8. pii: S0022-510X(15)02100.
    PubMed     Text format     Abstract available


  148. PAPATHANASIOU A, Messinis L, Zampakis P, Panagiotakis G, et al
    Thalamic atrophy predicts cognitive impairment in relapsing remitting multiple sclerosis. Effect on instrumental activities of daily living and employment status.
    J Neurol Sci. 2015 Sep 2. pii: S0022-510X(15)02051.
    PubMed     Text format     Abstract available


    August 2015
  149. NOVAKOVA L, Axelsson M, Malmestrom C, Zetterberg H, et al
    Reduced cerebrospinal fluid concentrations of oxysterols in response to natalizumab treatment of relapsing remitting multiple sclerosis.
    J Neurol Sci. 2015 Aug 29. pii: S0022-510X(15)02033.
    PubMed     Text format     Abstract available


  150. KALRON A, Frid L
    The "butterfly diagram": A gait marker for neurological and cerebellar impairment in people with multiple sclerosis.
    J Neurol Sci. 2015 Aug 20. pii: S0022-510X(15)00524.
    PubMed     Text format     Abstract available


  151. AVASARALA J, Zachariah P
    Vitamin D deficiency in multiple sclerosis: Should testing and treatment be based on racial background?
    J Neurol Sci. 2015 Aug 12. pii: S0022-510X(15)00514.
    PubMed     Text format     Abstract available


  152. LOVERA J, Ramos A, Devier D, Garrison V, et al
    Polyphenon E, non-futile at neuroprotection in multiple sclerosis but unpredictably hepatotoxic: Phase I single group and phase II randomized placebo-controlled studies.
    J Neurol Sci. 2015 Aug 7. pii: S0022-510X(15)00499.
    PubMed     Text format     Abstract available


  153. GUZZI G, Costa A, Pigatto P
    Serum NSE and multiple sclerosis.
    J Neurol Sci. 2015 Aug 7. pii: S0022-510X(15)00506.
    PubMed     Text format    


    July 2015
  154. FRNDAK SE, Irwin LN, Kordovski VM, Milleville K, et al
    Negative work events reported online precede job loss in multiple sclerosis.
    J Neurol Sci. 2015 Jul 26. pii: S0022-510X(15)00453.
    PubMed     Text format     Abstract available


  155. LOREFICE L, Murru, Fenu G, Corongiu D, et al
    A genetic association study of two genes linked to neurodegeneration in a Sardinian multiple sclerosis population: The TARDBP Ala382Thr mutation and C9orf72 expansion.
    J Neurol Sci. 2015 Jul 26. pii: S0022-510X(15)00457.
    PubMed     Text format     Abstract available


  156. VOLLMER T, Signorovitch J, Huynh L, Galebach P, et al
    The natural history of brain volume loss among patients with multiple sclerosis: A systematic literature review and meta-analysis.
    J Neurol Sci. 2015 Jul 13. pii: S0022-510X(15)00435.
    PubMed     Text format     Abstract available


  157. ARRU G, Caggiu E, Leoni S, Mameli G, et al
    Natalizumab modulates the humoral response against HERV-Wenv in a follow-up study of Multiple Sclerosis patients.
    J Neurol Sci. 2015 Jul 8. pii: S0022-510X(15)00428.
    PubMed     Text format     Abstract available


  158. HABEK M, Krbot Skoric M, Crnosija L, Adamec I, et al
    Brainstem dysfunction protects against syncope in multiple sclerosis.
    J Neurol Sci. 2015 Jul 2. pii: S0022-510X(15)00417.
    PubMed     Text format     Abstract available


    June 2015
  159. O'MALLEY PW, Mulla ZD, Nesic O
    Multiple sclerosis and breast cancer.
    J Neurol Sci. 2015 Jun 22. pii: S0022-510X(15)00374.
    PubMed     Text format     Abstract available


  160. PAPAIS-ALVARENGA RM, Pereira FF, Bernardes MS, Papais-Alvarenga M, et al
    Familial forms of multiple sclerosis and neuromyelitis optica at an MS center in Rio de Janeiro State, Brazil.
    J Neurol Sci. 2015 Jun 19. pii: S0022-510X(15)00375.
    PubMed     Text format     Abstract available


  161. SUNDGREN M, Wahlin A, Maurex L, Brismar T, et al
    Event related potential and response time give evidence for a physiological reserve in cognitive functioning in relapsing-remitting multiple sclerosis.
    J Neurol Sci. 2015 Jun 16. pii: S0022-510X(15)00366.
    PubMed     Text format     Abstract available


  162. ANDALIB S, Talebi M, Sakhinia E, Farhoudi M, et al
    Lack of association between mitochondrial DNA G15257A and G15812A variations and multiple sclerosis.
    J Neurol Sci. 2015 Jun 12. pii: S0022-510X(15)00363.
    PubMed     Text format     Abstract available


  163. LO AC, Ruiz JA, Koenig CM, Anderson BM, et al
    Effects of dalfampridine on multi-dimensional aspects of gait and dexterity in multiple sclerosis among timed walk responders and non-responders.
    J Neurol Sci. 2015 Jun 8. pii: S0022-510X(15)00349.
    PubMed     Text format     Abstract available


  164. SUGIYAMA A, Mori M, Masuda H, Uchida T, et al
    Trigeminal root entry zone involvement in neuromyelitis optica and multiple sclerosis.
    J Neurol Sci. 2015 Jun 3. pii: S0022-510X(15)00345.
    PubMed     Text format     Abstract available


    May 2015
  165. ALEXANDER JS, Chervenak R, Weinstock-Guttman B, Tsunoda I, et al
    Blood circulating microparticle species in relapsing-remitting and secondary progressive multiple sclerosis. A case-control, cross sectional study with conventional MRI and advanced iron content imaging outcomes.
    J Neurol Sci. 2015 May 28. pii: S0022-510X(15)00309.
    PubMed     Text format     Abstract available


  166. MEALY MA, Whetstone A, Orman G, Izbudak I, et al
    Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis.
    J Neurol Sci. 2015 May 17. pii: S0022-510X(15)00295.
    PubMed     Text format     Abstract available


  167. LA PUMA D, Llufriu S, Sepulveda M, Blanco Y, et al
    Long-term follow-up of immunotherapy-unresponsive recurrent tumefactive demyelination.
    J Neurol Sci. 2015;352.
    PubMed     Text format    


  168. BRIDOUX A, Creange A, Sangare A, Ayache SS, et al
    Impaired sleep-associated modulation of post-exercise corticomotor depression in multiple sclerosis.
    J Neurol Sci. 2015 May 10. pii: S0022-510X(15)00272.
    PubMed     Text format     Abstract available


  169. MITOLO M, Venneri A, Wilkinson ID, Sharrack B, et al
    Cognitive rehabilitation in multiple sclerosis: A systematic review.
    J Neurol Sci. 2015 May 9. pii: S0022-510X(15)00269.
    PubMed     Text format     Abstract available


  170. ANDALIB S, Talebi M, Sakhinia E, Farhoudi M, et al
    Mitochondrial DNA T4216C and A4917G variations in multiple sclerosis.
    J Neurol Sci. 2015 May 7. pii: S0022-510X(15)00260.
    PubMed     Text format     Abstract available


  171. MOROSO A, Deloire MS, Ruet A, Ouallet JC, et al
    Does cerebrospinal fluid analysis add predictive value to magnetic resonance imaging for long term irreversible disability in patients with early multiple sclerosis?
    J Neurol Sci. 2015 May 2. pii: S0022-510X(15)00254.
    PubMed     Text format     Abstract available


  172. MOTL RW, Hubbard EA, Sreekumar N, Wetter NC, et al
    Pallidal and caudate volumes correlate with walking function in multiple sclerosis.
    J Neurol Sci. 2015 May 1. pii: S0022-510X(15)00251.
    PubMed     Text format     Abstract available


    April 2015
  173. SERGOTT RC, Bennett JL, Rieckmann P, Montalban X, et al
    ATON: results from a Phase II randomized trial of the B-cell-targeting agent atacicept in patients with optic neuritis.
    J Neurol Sci. 2015;351.
    PubMed     Text format     Abstract available


    February 2015
  174. MCGEE J, Minagar A
    Co-existence of tumefactive MS and hepatitis C: A need for further screening and new therapeutic challenge.
    J Neurol Sci. 2015;349.
    PubMed     Text format    


  175. PENG JT, Cong HR, Yan R, Kong XY, et al
    Neurological outcome and predictive factors of idiopathic optic neuritis in China.
    J Neurol Sci. 2015;349.
    PubMed     Text format     Abstract available


  176. FRAU J, Cossu D, Coghe G, Lorefice L, et al
    Role of interferon-beta in Mycobacterium avium subspecies paratuberculosis antibody response in Sardinian MS patients.
    J Neurol Sci. 2015;349.
    PubMed     Text format     Abstract available


    January 2015
  177. AVASARALA JR
    Clinically isolated syndrome--Rethinking the diagnosis.
    J Neurol Sci. 2015;353.
    PubMed     Text format     Abstract available


    October 2014
  178. PULA JH, Kattah JC, Keung B, Wang H, et al
    Longitudinally extensive optic neuritis in neuromyelitis optica spectrum disorder.
    J Neurol Sci. 2014;345.
    PubMed     Text format     Abstract available


  179. KIMURA MC, Doring TM, Rueda FC, Tukamoto G, et al
    In vivo assessment of white matter damage in neuromyelitis optica: a diffusion tensor and diffusion kurtosis MR imaging study.
    J Neurol Sci. 2014;345.
    PubMed     Text format     Abstract available


    September 2014
  180. WILSON L, Loucks A, Bui C, Gipson G, et al
    Patient centered decision making: use of conjoint analysis to determine risk-benefit trade-offs for preference sensitive treatment choices.
    J Neurol Sci. 2014;344.
    PubMed     Text format     Abstract available


  181. HELLMANN MA, Lev N, Lotan I, Mosberg-Galili R, et al
    Tumefactive demyelination and a malignant course in an MS patient during and following fingolimod therapy.
    J Neurol Sci. 2014;344.
    PubMed     Text format     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Multiple Sclerosis is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: